TWiV 1074: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses the outcomes of SARS-CoV-2, influenza and respiratory syncytial virus infection in pediatric communities under the age of 18 years, the treatment of infants with the human monoclonal anti-respiratory syncytial virus antibody to prevent hospitalizations, most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US, how the SARS-CoV-2/COVID-19 pandemic affected school attendance and child healthcare, how exposure length influenced transmission of SARS-CoV-2, how the durability of the anti-SARS-CoV-2 antibody response to protect against virus re-infection, if administration of oral antiviral therapy affected viral rebound in either the unvaccinated or vaccinated populations, as well as a reminder of the ineffectiveness of antibiotics for treating COVID-19 and the effect of vaccination on post-COVID conditions in children between 5-17 years old.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Pediatric outcomes SARS-CoV-2, flu, RSV (JAMA Peds.)
- SARS-CoV-2 vs Flu (Wired)
- Anti-RSV antibody treatment for infants (NEJM)
- Respiratory disease surveillance (CDC)
- RSV surveillance (CDC)
- RSV national trend (CDC)
- Influenza/flu surveillance (CDC)
- COVID-19 hospital admissions (CDC)
- COVID-19 national trend (CDC)
- COVID-19 wastewater testing (biobot)
- COVID-19 school attendance (JPEIDS)
- COVID-19 pandemic effects children health care (JPEIDS)
- Digitally measuring transmission (Nat)
- Antibody titers and re-infection (CMI)
- Oral antiviral and SARS-CoV-2 rebound (MMWR)
- Rebound after antiviral controlled trial (MMWR)
- Vaccination and antiviral therapy (OFID)
- Antivirals and hospitalization (JMV)
- Antivirals molnupiravir (JMV)
- Convalescent plasma and the immunocompromised guidelines (IDSOciety)
- Steroid and the cytokine storm (OFID)
- Anticoagulation guidelines (hematology.org)
- Unnecessary antibiotics (NEJM)
- Vaccination and long COVID (OFID)
- RSV vaccination (MMWR)
- Antivirals and chronic kidney disease (CID)
- Early administraton of molnupiravir versus ritonavir-boosted nirmatrelvir (Lancet)
- Contribute to our MicrobeTV fundraiser at PWB
- Letters read on TWiV 1074
- Dr. Griffin's COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
More description
In his weekly clinical update, Dr. Griffin discusses the outcomes of SARS-CoV-2, influenza and respiratory syncytial virus infection in pediatric communities under the age of 18 years, the treatment of infants with the human monoclonal anti-respiratory syncytial virus antibody to prevent hospitalizations, most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US, how the SARS-CoV-2/COVID-19 pandemic affected school attendance and child healthcare, how exposure length influenced transmission of SARS-CoV-2, how the durability of the anti-SARS-CoV-2 antibody response to protect against virus re-infection, if administration of oral antiviral therapy affected viral rebound in either the unvaccinated or vaccinated populations, as well as a reminder of the ineffectiveness of antibiotics for treating COVID-19 and the effect of vaccination on post-COVID conditions in children between 5-17 years old.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Pediatric outcomes SARS-CoV-2, flu, RSV (JAMA Peds.)
- SARS-CoV-2 vs Flu (Wired)
- Anti-RSV antibody treatment for infants (NEJM)
- Respiratory disease surveillance (CDC)
- RSV surveillance (CDC)
- RSV national trend (CDC)
- Influenza/flu surveillance (CDC)
- COVID-19 hospital admissions (CDC)
- COVID-19 national trend (CDC)
- COVID-19 wastewater testing (biobot)
- COVID-19 school attendance (JPEIDS)
- COVID-19 pandemic effects children health care (JPEIDS)
- Digitally measuring transmission (Nat)
- Antibody titers and re-infection (CMI)
- Oral antiviral and SARS-CoV-2 rebound (MMWR)
- Rebound after antiviral controlled trial (MMWR)
- Vaccination and antiviral therapy (OFID)
- Antivirals and hospitalization (JMV)
- Antivirals molnupiravir (JMV)
- Convalescent plasma and the immunocompromised guidelines (IDSOciety)
- Steroid and the cytokine storm (OFID)
- Anticoagulation guidelines (hematology.org)
- Unnecessary antibiotics (NEJM)
- Vaccination and long COVID (OFID)
- RSV vaccination (MMWR)
- Antivirals and chronic kidney disease (CID)
- Early administraton of molnupiravir versus ritonavir-boosted nirmatrelvir (Lancet)
- Contribute to our MicrobeTV fundraiser at PWB
- Letters read on TWiV 1074
- Dr. Griffin's COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.